Nuveen LLC Acquires Shares of 319,919 Establishment Labs Holdings Inc. $ESTA

Key Points

• Nuveen LLC has made a new investment in Establishment Labs Holdings Inc., acquiring 319,919 shares valued at approximately $13.05 million, representing about 1.11% ownership of the company.
• Analysts have mixed views on Establishment Labs, with a consensus rating of "Moderate Buy" and various price targets ranging from $47.00 to $70.00.
• The company's latest quarterly earnings report indicated a revenue increase of 16.1% year-over-year, though it missed EPS expectations with a loss of ($0.57) per share.

Nuveen LLC acquired a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 319,919 shares of the company's stock, valued at approximately $13,054,000. Nuveen LLC owned 1.11% of Establishment Labs at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Establishment Labs in the 1st quarter valued at $207,000. New York State Common Retirement Fund purchased a new stake in shares of Establishment Labs in the 1st quarter valued at $894,000. Northern Trust Corp raised its holdings in shares of Establishment Labs by 53.9% in the 4th quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after buying an additional 9,865 shares during the period. Swiss National Bank raised its holdings in shares of Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock valued at $1,591,000 after buying an additional 500 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Establishment Labs by 15.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after purchasing an additional 6,307 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA traded up $0.68 during trading hours on Wednesday, reaching $42.44. The stock had a trading volume of 261,793 shares, compared to its average volume of 495,107. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -13.91 and a beta of 0.83. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. Establishment Labs Holdings Inc. has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The firm has a 50-day moving average of $41.16 and a 200-day moving average of $37.57.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The firm's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period last year, the company earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Equities research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen cut Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. BTIG Research assumed coverage on Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 target price for the company. Canaccord Genuity Group assumed coverage on Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 target price for the company. Finally, Citigroup boosted their target price on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Establishment Labs has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.